Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

37.68 -5.53 (-12.80%)

Streaming Delayed Price Updated: 1:26 PM EST, Jan 8, 2026 Add to My Watchlist

Price and Volume

Volume	139,707
Open	42.70
Bid (Size)	37.14 (100)
Ask (Size)	37.91 (200)
Prev. Close	43.21
Today's Range	37.36 - 42.70
52wk Range	7.255 - 45.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Sionna Therapeutics, Inc.

Via GlobeNewswire

A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million ↗

January 03, 2026

This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions.

Via The Motley Fool

Performance

YTD	-3.9%	-3.9%
1 Month	-7.5%	-7.5%
3 Month	+32.2%	+32.2%
6 Month	+80.0%	+80.0%
1 Year	+50.7%	+50.7%

More News

Sionna Therapeutics to Participate in Upcoming December Investor Conferences

November 24, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar ↗

September 08, 2025

Via Stocktwits

Sionna Therapeutics Reports Third Quarter 2025 Financial Results

November 05, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics to Participate in Upcoming November Investor Conferences

November 04, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 28, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 27, 2025

Via Benzinga

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

October 24, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

October 21, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

October 01, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

September 08, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

August 11, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday ↗

July 02, 2025

Via Benzinga

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

June 06, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial ↗

June 04, 2025

Via Benzinga

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

June 04, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 03, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

May 22, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics Reports First Quarter 2025 Financial Results

May 12, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

April 30, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 22, 2025

Via Benzinga

Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

April 17, 2025

Via Benzinga

Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗

April 17, 2025

Via Benzinga

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

March 20, 2025

From Sionna Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Sionna Therapeutics, Inc. - Common Stock publicly traded?

Yes, Sionna Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Sionna Therapeutics, Inc. - Common Stock trade on?

Sionna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sionna Therapeutics, Inc. - Common Stock?

The ticker symbol for Sionna Therapeutics, Inc. - Common Stock is SION on the Nasdaq Stock Market

What is the current price of Sionna Therapeutics, Inc. - Common Stock?

The current price of Sionna Therapeutics, Inc. - Common Stock is 37.68

When was Sionna Therapeutics, Inc. - Common Stock last traded?

The last trade of Sionna Therapeutics, Inc. - Common Stock was at 01/08/26 01:26 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.